REPORT AT 30 JUNE 2020

Madrid, 30 July 2020

1H20 HIGHLIGHTS

Corporate

- Total Group revenues amounted to €169.1 million (vs. €41.4 million in 1H19).
- Licensing revenues totaled €115.0 million in the first half, mainly from the licensing agreement with Jazz Pharmaceuticals. In accordance with IFRS 15 on recognition of upfront and milestone payments, a total of €112.4 million in revenues had been recognized under this agreement as of 30 June 2020.
- Group net sales amounted to €52.6 million, an increase of 35% over the first half of 2019 (€39.0 million).
- The Shareholders' Meeting of PharmaMar approved the reverse-split and exchange of Company shares for newly-issued shares in the proportion of one new share for every 12 pre-existing shares of the Company, which took place on 22 July 2020.
- On 30 June, the Company distributed an ordinary dividend of 4 cent per share.
- Rating agency Axesor upgraded PharmaMar from B+ to BB-, with a positive outlook.

Oncology

- In June the US Food and Drug Administration (FDA) granted accelerated approved for Zepzelca™ (lurbinectedin) for the treatment of relapsed small cell lung cancer. With this approval, the company achieved one of the milestones contemplated in the licensing agreement with Jazz Pharmaceuticals, triggering a payment of USD 100 million (€88.5 million).
- The APLICOV-PC clinical trial with Aplidin® for treating COVID-19 commenced in Spain in April.
- In June, Australia's Therapeutic Goods Administration (TGA) granted lurbinectedin "Provisional Approval Pathway" designation, which allows for a faster review for approval of medicines that cover unmet therapeutic needs.
- PharmaMar signed an exclusive distribution and commercialization with Impilo Pharma AB (Inmedic Pharma) for anti-tumor drug lurbinectedin in the United Kingdom, Ireland, the Nordic countries, and some countries in Eastern Europe, the Middle East and North Africa.

Diagnostics

- Genómica realized €5.6 million in revenues, 110% more than in the first half of 2019 (€2.7 million).
- Genómica obtained the CE mark for its COVID-19 coronavirus diagnostics kits, certifying that they fulfil the essential requirements for in vitro diagnostic products, and it began marketing them in March.

Mª Luisa de Francia
CFO
PHARMA MAR, S.A.
Plaza Descubridor Diego de Ordás, 3
Madrid
Telephone 914444500

José Luis Moreno
Head of Capital Markets and Investor Relations
PHARMA MAR, S.A.
Plaza Descubridor Diego de Ordás, 3
Madrid
Telephone 914444500

FIGURES TO JUNE 2020

	06/30/2020	06/30/2019	Var.
Oncology Sales	46.950	36.291	29%
Commercial Sales	*44.334*	*35.777*	24%
API sales	*2.616*	*514*	409%
Diagnostics Sales	5.639	2.689	110%
Sales	**52.589**	**38.980**	**35%**
Royalties	**1.420**	**1.654**	**-14%**
Licences	**114.966**	**629**	
Other (Diagnostics)	**135**	**143**	
TOTAL REVENUES	**169.110**	**41.406**	**308%**

(Thousand euro)

Total Group revenues

Revenues in the oncology segment, amounting to €47.0 million (vs.€36.3 million in 1H19), were almost entirely from Yondelis® sales but also include compassionate-use sales of Zepzelca™ (lurbinectedin) in some European countries, amounting to €5.9 million, and sales of Zepzelca™ vials to our partners, amounting to €1.5 million. Sales of the Yondelis raw materials to partners (Janssen and Taiho) amounted to €2.6 million in the first half of 2020 (vs.€0.5 million in the same period of 2019). Sales in oncolgy increased by 29% year-on-year.

Revenues in the diagnostics segment increased by 110% year-on-year to €5.6 million (vs. €2.7 million in the first half of 2019), mainly as a result of sales of the new COVID-19 diagnosis kit, which was released in March, and the distribution of the IgM/IgG antibody test for COVID-19.

Royalty revenues correspond to the Oncology segment. Royalties received from Janssen Products and Taiho Pharmaceutical Co for sales of Yondelis® in the United States, Japan and the rest of the world except the European Union amounted to €1.4 million in the first half of 2020 (vs. €1.7 million in the same period of 2019).

Revenues from licensing and other co-development agreements, which also correspond entirely to the Oncology, amounted to €115 million in the first half of 2020, mostly under the licensing agreement for Zepzelca™ (lurbinectedin) in the United States with Jazz Pharmaceuticals.

The licensing agreement for Zepzelca™ (lurbinectedin) signed with Jazz Pharmaceuticals in December 2019 came into force in January. PharmaMar collected an upfront payment of USD 200 million (€181 million). In June, Zepzelca™ (lurbinectedin) was approved for commercialization in the US by the FDA under the accelerated approval pathway. As a result, PharmaMar collected a regulatory milestone of USD 100 million (€88.5 million) from Jazz Pharmaceuticals. By application of the accounting standard on revenue recognition (IFRS 15), revenues from the licensing agreement are recognized on the basis of the degree of progress and/or compliance with the commitments acquired by PharmaMar under the agreement; consequently, a total of €112.4 million in revenues had been recognized as of 30 June 2020. Another €3 million were recognized as revenues under other licensing agreements.

As a result, **total revenues** amounted to €169.1 million in the first half of 2020, compared with €41.4 million in the same period of 2019.

Gross margin and EBITDA

The Group's gross margin was 92.7% of revenues in the first half of 2020 (vs. 93.3% in the same period of 2019). (Calculated with respect to sales only, not including royalties or licensing revenues).

EBITDA in the period is calculated as follows:

	6/30/20	6/30/19
Net result of continuing operations	**113.789**	**(19.112)**
Income tax	1.501	3.353
Net financial income	(265)	2.081
Depreciation and amortization	3.739	3.894
EBITDA	**118.764**	**(9.784)**

(Thousand euro)

(EBITDA includes all revenues and expenses from business activities except for depreciation and amortization, provisions, net interest income and tax expenses).

R&D expenditure

R&D expenditure declined in year-on-year terms, from €27.9 million in the first half of 2019 to €24.3 million in the first half of 2020. The Oncology area spent €22.7 million on R&D, compared with €24.6 million in the same period of the previous year. That decline was due mainly to the fact that the first half of 2019 included expenditure on the Atlantis and Basket trials with Zepzelca™ (lurbinectedin) in small cell lung cancer, enrolment for which had concluded by the first half of 2020. The decline was also attributable, although to a lesser extent, to delays caused by the COVID-19 pandemic, which made it impossible to make visits for the purposes of monitoring and conclusion of processes. The reduction in R&D spending in the Diagnostics segment (€1.4 million) was due to conclusion of the NEDXA point-of-care diagnostics platform, with priority being given to development of the conventional CLART platform. The reduction in R&D spending in the RNAi segment (€0.3 million) is temporary, since the activities in the first half of 2020 were mainly preclinical, whereas expenditure in the same period of 2019 included the HELIX Phase III trial with tivanisiran. The protocol for a new Phase III trial with tivanisiran is currently being prepared.

The breakdown of R&D expenditure is shown in the next table:

	6/30/20	6/30/19	Difª	
R&D expenses	**24.251**	**27.916**	**-3.665**	**-13,1%**
Oncology	22.686	24.646	-1.960	-8,0%
Diagnostics	279	1.699	-1.420	-83,6%
RNAi	1.286	1.571	-285	-18,1%

(Thousand euro)

Marketing and commercial expenses

Group marketing and commercial expenses amounted to €11.5 million in the first half of 2020, 9.6% less than in the same period of 2019 (€12.7 million), mainly as a result of fewer trips to specialized conferences due to COVID-19.

Income from discontinued operations

In June 2019, the Group divested its entire stake in Zelnova Zeltia, a company in the consumer chemicals business. The consolidated result of that divestment was -€2.2 million.

Income from continuing operations

Profit in the first half of 2020 (€113.8 million) reflects higher revenues, mainly under licensing agreements (€115 million in the first half of 2020, compared with €0.6 million in the same period of 2019). Additionally, sales increased by €13.6 million in the first half of 2020, driven by both Oncology and Diagnostics. Meanwhile, operating expenses overall declined by €1.1 million year-on-year. This resulted in a profit of €113.8 million in the first half of 2020, compared with a loss of -€21.3 in the same period of 2019.

Cash and Debt

As of 30 June 2020, the net cash position (cash + cash equivalents + current financial assets) amounted to €228.1 million (vs. €20.9 million at 2019 year-end). Including non-current financial assets, the total was €249.2 million as of 30 June 2020 (€21.9 million as of 2019 year-end).

For the purpose of comparing balance sheet figures, the Group's total net interest-bearing debt at amortized cost is detailed below:

	6/30/2020	12/31/2019
Non current debt	**40.927**	**53.063**
Bank debt	6.109	15.291
Obligations and bonds	16.574	16.549
Govt. Agencies: R&D funding	18.244	21.223
Current debt	**18.524**	**29.655**
Credit facilities	5.197	11.583
Effects and certifications	611	2.241
Bank loan	6.845	10.497
Govt. Agencies: R&D funding	5.092	4.883
Interest and others	779	451
Total financial debt	**59.451**	**82.718**
Cash&cash equivalents + non current and current financial investment	**249.158**	**21.924**
TOTAL NET CASH / (DEBT)	**189.707**	**(60.794)**

(Thousand euro)

There were two receipts in the first half of 2020 under the Zepzelca™ (lurbinectedin) licensing agreement with Jazz Pharmaceuticals: a €181 million upfront payment, and an €88.5 million milestone payment triggered by FDA approval.

Two bank loans amounting to €9.0 million as of 1 January 2020 were repaid early during the period, and repayments of other loans from banks and official bodies amounted to €7.2 million.

As of 30 June 2020, the Group had €10.3 million available in credit lines (€2.1 million as of 31 December 2019).

Effects of COVID-19

The COVID-19 pandemic had the following effects on the Group's activities: in March, the Diagnostics segment developed its own diagnostic kits and signed a distribution agreement for the fast diagnostic test of IgM and IgG antibodies to COVID-19. As a result, this segment booked €5.6 million in revenues in the period, a 110% increase year-on-year. The Oncology segment commenced the APLICOV-PC clinical trial with Aplidin® (plitidepsin) for treating COVID-19 patients, whose goal is to assess the efficacy and safety of plitidepsin in COVID-19 patients requiring hospital admission. At the date of this report, the trial was still enrolling patients.

The Group did not need to avail itself of furlough or layoff measures.
Commercial activity was unaffected by the situation; in fact, Oncology sales increased by 29% in the first half.

Following suitable analysis, it was concluded that it was not necessary to adjust asset or liability valuations. Production capacity was not affected, and both the Oncology and Diagnostics segments have sufficient raw materials and inventories to maintain regular sales of Yondelis, supply launch product of Zepzelca™ (lurbinectedin) and continue with the clinical trials that are under way, and to continue selling diagnostic kits, respectively. All the Group's material agreements remain in force in the same terms.

No bad debts are expected in the area of trade accounts receivable. A significant percentage of the Group's sales are to government institutions; accordingly, default risk is low.

As of 30 June 2020, the Group had a net cash position of €189.7 million (net of current and non-current debt), and €10.3 million available in credit lines. Debt maturities in the next twelve months amount to €12.6 million. None of the existing loans is subject to covenants.

At the date of this report, the Group's ability to continue as a going concern is well assured.

The directors and managers of the Group constantly monitor the situation in order to anticipate any financial or non-financial impacts that might arise.

BUSINESS PERFORMANCE.

Below is an overview of research and development activities in the first half of 2020.

1.- Oncology segment: PharmaMar

A) YONDELIS®:

In May, PharmaMar signed an agreement with Key Oncologics for the commercialization of Yondelis in South Africa, Namibia and Botswana. In June, PharmaMar signed a licensing agreement for commercialization of Yondelis in the territories of Taiwan, Hong Kong and Macao.

In January, it signed an agreement with Valeo Pharma for the commercialization of Yondelis® in Canada.

Soft tissue sarcoma

As of 30 June 2020, 25 post-authorization trials were under way, 15 of them active (11 enrolling new patients). The other trials were in the process of closing or data analysis or were pending the presentation of results. Three additional trials are scheduled to commence in the coming months.

The LMS 02 investigator initiated trial (Phase II, with trabectedin + doxorubicin as first-line treatment of patients with leiomyosarcoma, including uterine) was accepted for an oral presentation at ASCO 2020.

Ovarian cancer

There were a total of 14 trials in this indication in the first half of 2020: 7 were active, 3 were closing, 2 had closed in the period, and 1 was in the activation phase.

B) Zepzelca™ (lurbinectedin)

Small-cell lung cancer

On 15 June 2020 the US Food and Drug Administration (FDA) approved Zepzelca™ (lurbinectedin) for treating patients with small-cell lung cancer who had experienced progression after platinum-based chemotherapy. Lurbinectedin benefited from accelerated approval based on the Overall Response Rate (ORR) and Duration of Response (DoR). The FDA approval was based on data from an open multi-center single-arm trial in which the drug was tested as a single agent in 105 platinum-sensitive and platinum-resistant adult patients with relapsed small cell lung cancer.

As a result of this approval, Jazz Pharmaceuticals was able to make Zepzelca™ (lurbinectedin) commercially available in the United States early in July this year. PharmaMar will collect royalties on net sales ranging between high teens to 30%. As indicated in the section on Revenues, that accelerated approval resulted in PharmaMar collecting €88.5million (USD 100 million) and it could collect an additional USD 150 million once full approval is obtained as well as other milestones related to future sales or approval in the US.

ATLANTIS trial

The ATLANTIS pivotal Phase III trial compares the activity and safety of the combination of lurbinectedin, an anti-tumor drug of marine origin, plus doxorubicin, against physician's choice of topotecan or CAV (cyclophosphamide, adriamycin and vincristine) for treating patients with small cell lung cancer who have relapsed after a first round of platinum treatment.

The trial is currently monitoring patient survival, which is its primary endpoint. The data from this trial are expected to be available in the second half of 2020.

Basket trial

Enrolment concluded for the Phase II basket trial with Lurbinectedin as monotherapy in selected indications, such as small cell lung cancer, neuroendocrine tumors, carcinoma of the head and neck, germ cell cancer, endometrial cancer, bile duct cancer, cancer of unknown primary, Ewing sarcoma and breast cancer with BRCA 1/2 mutation, and patient progress is currently being monitored.

Combination trials

As regards Phase I combination trials, recruitment was completed for the combinations with doxorubicin, cisplatin, capecitabine and paclitaxel with or without bevacizumab.

Recruitment continues on schedule for the Phase I trial in combination with irinotecan and with atezolizumab.

The American Society of Clinical Oncology (ASCO) accepted a poster discussion from PharmaMar on the combination with irinotecan for its annual meeting, which was held online in May 2020.

Phase I trial in Japan

This trial, designed to ascertain the dosage for Lurbinectedin in Japanese patients, attained its primary endpoint by determining the recommended dose for that population. Enrolment concluded and the treated patients are in the process of being evaluated.

C) APLIDIN®

The APLICOV-PC trial with Aplidin® (plitidepsin) for treating COVID-19 patients commenced in April; the goal is to assess the efficacy and safety of plitidepsin in COVID-19 patients requiring hospital admission.

Aplidin® produced positive results with nanomolar potency in in vitro trials with human coronavirus HCoV-229E at Spain's National Centre for Biotechnology (CNB), which forms part of the Spanish National Research Council (CSIC). These studies confirmed the hypothesis that the therapeutic target of Aplidin® (EF1A) is crucial for the multiplication and propagation of the virus. These results were corroborated by Boryung Pharmaceutical, PharmaMar's partner in South Korea.

D) PM184

The Phase I dose escalation trial assessing the combination of PM184 with gemcitabine, conducted at two centers (one in Spain and one in the United States), concluded enrolment and is now in the patient monitoring phase.

E) PM14

Recruitment continues for the clinical development program with this new molecule. The main endpoint of this Phase I trial is to identify the optimal dose for administration of PM14 in patients with advanced solid tumors, and to define the compound's safety profile and assess its pharmacokinetics and pharmacogenetics in treated patients.

2.- Diagnostics Genómica

Genómica's 1H20 revenues amounted to €5.8 million (€2.9 million euro in 1H19). This growth was driven basically by the sale of COVID-19 molecular diagnostic kits, which amounted to €2.6 million in the first half, and the distribution of the fast test for detecting IgM/IgG antibodies to COVID-19, whose sales amounted to €0.5 million in the period.

On 6 March 2020, Genómica obtained the CE mark for commercialization of its COVID-19 diagnostic kits: "CLART®COVID-19" (based on Genómica's CLART® technology) and "qCOVID-19" (based on Real-Time technology).

In June, an agreement was signed with Medsol Corporation for Medical Equipment Import and Trading granting exclusive rights to import Genómica products into Egypt.

3.- RNA interference: Sylentis

During the second quarter of 2020, the Company continued to work on the regulatory documentation, clinical trial protocol and selection of a CRO to manage and monitor the trial in the United States in order to advance with the clinical development of Tivanisiran for treating dry eye syndrome.

Additionally, all the regulatory documentation and the design of the Phase I trial with SYL1801 were completed in the second quarter of 2020, and the trial is due to commence in the second half of 2020. The company is also working on other RNAi candidates for topical treatment of retinal diseases. Those candidates' efficacy has been analyzed using preclinical models of a number of retinal pathologies.

BALANCE SHEET *(Thousand euro)*	06/30/2020	12/31/2019
ASSETS		
Non-current assets	**92.757**	**74.730**
Property, plant & equipment	21.783	22.452
Investment properties	845	845
Intangible assets	4.785	6.074
Right-of-use assets	3.335	3.345
Goodwill	0	0
Long-term financial assets	21.052	1.029
Deferred tax assets	40.956	40.984
Current assets	**259.470**	**49.977**
Inventories	9.576	8.902
Customer and other receivables	18.282	11.530
Current financial assets	19.214	3.257
Other current assets	3.506	8.649
Cash & cash equivalents	208.892	17.638
TOTAL ASSETS	**352.227**	**124.706**

BALANCE SHEET *(Thousand euro)*	06/30/2020	12/31/2019
EQUITY		
Shareholders' equity	**107.434**	**11.373**
Share capital	11.132	11.132
Share premium	71.278	71.278
Treasury shares	(11.412)	(1.500)
Revaluation and other reserves	13	15
Retained earnings and other reserves	36.422	(69.552)
Minority interest	**(3.936)**	**(3.918)**
TOTAL EQUITY	**103.497**	**7.455**
LIABILITIES		
Non-current liabilities	**140.282**	**56.810**
Financial debt	40.927	53.063
Lease liabilities	1.898	1.719
Non-current deferred revenues	97.284	1.851
Other non-current liabilities	174	177
Current liabilities	**108.447**	**60.441**
Supplier and other accounts payables	15.170	19.332
Financial debt	18.524	29.655
Lease liabilities	1.492	1.678
Provisions for other liabilities & expenses	4.561	5.734
Current deferred revenues	62.102	1.465
Other current liabilities	6.597	2.577
TOTAL LIABILITIES	**248.729**	**117.251**
TOTAL LIABILITIES AND EQUITY	**352.227**	**124.706**

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS		
Thousand euro	**06/30/2020**	**06/30/2019**
Revenue:		
Revenue from contracts with customers	52.589	38.980
Revenue from licensing and development agreements (excluding royalties)	114.966	629
Royalties	1.420	1.654
Other	135	143
	169.110	**41.406**
Cost of sales	(3.854)	(2.593)
Marketing expenses	(11.495)	(12.736)
General and administrative expenses	(8.439)	(6.934)
Research and development expenses	(24.252)	(27.916)
Net impairment on financial assets	(167)	(5)
Other operating expenses	(6.304)	(5.430)
Other results	426	531
Net operating result	**115.025**	**(13.677)**
Net financial results	**265**	**(2.082)**
Result of the period before income taxes	**115.290**	**(15.759)**
Income tax benefit / (expense)	(1.501)	(3.353)
Result for the period from continuing operations	**113.789**	**(19.112)**
Result for the period from discontinued operations	**0**	**(2.217)**
Equity holders of the parent company	0	(2.217)
Result for the period	113.789	(21.329)
Equity holders of the parent company	**113.808**	**(21.320)**
Non-controlling interests	(19)	(9)

CONSOLIDATED CASH FLOW STATEMENT	EUR
	06/30/2020
TOTAL NET OPERATING CASH FLOW	**268.341**
Income before taxes	**115.290**
Profit before tax from continuing operations	*115.290*
Adjustments for:	**3.353**
Depreciation and amortization	3.709
Provision for impairment of accounts receivable	35
Finance income	(98)
Finance costs	1.606
Share based payments	122
Deferred income - grants	(248)
Effects of exchange rate changes	(1.773)
Changes in working capital:	**151.206**
Inventories	(675)
Trade and other receivables	(6.787)
Other assets and liabilities	7.685
Trade and other accounts payable	(5.335)
Deferred or accrual items	156.318
Other cash flow from operations:	**(1.508)**
Financial expenses	(1.606)
Financial revenues	98
TOTAL NET INVESTING CASH FLOW	**(36.941)**
Investments payments:	**(36.941)**
Purchases of property, plant & equipment and intangible assets	(960)
Other financial assets	(35.981)
TOTAL NET FINANCING CASH FLOW	**(41.914)**
Collections and (payments) in connection with equity instruments:	**(9.043)**
Acquisition	(18.932)
Disposal	9.889
Collections and (payments) in connection with financial liabilities:	**(16.835)**
Loans received	76
Refund and amortization	(16.911)
Other financing cash flow:	**(7.219)**
Other financing receipts / (payments)	(7.219)
Dividends paid to company's shareholders	**(8.817)**
Effects of exchange rate changes on cash and cash equivalents	**1.767**
TOTAL NET CASH FLOW	**191.253**
Beginning balance of cash and cash equivalents	17.638
ENDING BALANCE OF CASH AND CAHS EQUIVALENTS	**208.892**

EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS OF PHARMA MAR, S.A. FOR THE FIRST HALF OF 2020.

1. General information

Pharma Mar, S.A. is the company that resulted from the merger of Zeltia, S.A. (absorbed company) into Pharma Mar, S.A. (acquiring company). Pharma Mar, S.A., the Group's parent company (hereinafter, "PharmaMar" or "the Company"), was incorporated as a limited company in Spain for an indefinite period on 30 April 1986. Its registered offices are located in Colmenar Viejo (Madrid) at Avenida de los Reyes, 1 (Pol. Industrial La Mina – norte).

PharmaMar's main activity is research, development, production and commercialization of bio-active principles of marine origin for application in oncology, as well as management, support and development of its investees, in the diagnostics and RNA interference areas, and investees whose object is the commercialization of oncology products in Europe.

Until June 2019, the Group had another line of business — consumer chemicals — which it has divested in the last two years.

The interim financial statements for the first half of 2020 have not been audited.

Significant events in the first half of 2020

The licensing agreement for Zepzelca™ (lurbinectedin) signed with Jazz Pharmaceuticals in December 2019 came into force in January 2020. In addition to milestone payments and royalties, the agreement provided for an upfront payment of USD 200 million (€181 million), which PharmaMar collected in February.

Also in February, the US Food & Drug Administration (FDA) granted priority review status to a new drug application (NDA) for accelerated approval of Lurbinectedin for treating patients with relapsed small-cell lung cancer who had experienced progression after platinum-based therapy.

In June, the FDA approved Zepzelca™ (lurbinectedin) for that indication under the accelerated approval process on the basis of Overall Response Rate (ORR) and Duration of Response (DoR). The licensing agreement with Jazz Pharmaceuticals provided for a payment of USD 100 million (€88.5 million) in the event of accelerated approval by the FDA, which took place in June.

In March 2020, Genómica obtained the CE mark for commercialization of its PCR diagnostic kits for COVID-19. It also signed a distribution agreement with a Korean company for the distribution in Spain of fast tests for detecting antibodies to COVID-19. These sales are directly related to the situation of the COVID-19 pandemic, and their future trend cannot be predicted at present.

Effects of COVID-19

The COVID-19 pandemic had the following effects on the Group's activities: in March, the Diagnostics segment developed its own diagnostic kits and signed a distribution agreement for the fast test for detecting IgM/IgG antibodies to COVID-19. As a result, this segment booked €5.6 million in revenues in the period, a 110% increase year-on-year. The Oncology segment commenced the APLICOV-PC clinical trial with Aplidin® (plitidepsin) for treating COVID-19 patients, whose goal is to assess the efficacy and safety of plitidepsin in COVID-19 patients requiring hospitalization. At the date of this report, the trial was still enrolling patients.

The Group did not need to avail itself of furlough or layoff measures.
Commercial activity was unaffected by the situation; in fact, Oncology sales increased by 29% in the first half.

Following suitable analysis, it was concluded that it was not necessary to adjust asset or liability valuations. Production capacity was not affected, and both the Oncology and Diagnostics segments have sufficient raw materials and inventories to maintain regular sales of Yondelis, launch Zepzelca™ (lurbinectedin) and continue with

the clinical trials that are under way, and to continue selling diagnostic kits, respectively. All the Group's material agreements remain in force in the same terms.

No bad debts are expected in the area of trade accounts receivable. A significant percentage of the Group's sales are to government institutions; accordingly, default risk is low.

As of 30 June 2020, the Group had a net cash position of €189.7 million (net of current and non-current debt), and €10.3 million available in credit lines. Debt maturities in the next twelve months amount to €12.6 million. None of the existing loans is subject to covenants.

At the date of this report, the Group's ability to continue as a going concern is well assured.

The directors and managers of the Group constantly monitor the situation in order to anticipate any financial or non-financial impacts that might arise.

Consolidation scope

There were no changes in the consolidation scope in the first half of 2020.

In June 2019, PharmaMar sold wholly-owned subsidiary ZelnovaZeltia, S.A., which manufactured and marketed insecticide products for domestic use and other home care products. Accordingly, the income statements both of Pharma Mar, S.A. and the consolidated group as of 30 June 2019 contain the transactions of that subsidiary under discontinued operations.

2. Basis of presentation, accounting standards, judgments, and material accounting estimates.

A.- The interim separate financial statements for the first half of 2020 were prepared in accordance with Spain's New General Accounting Plan (NPGC), which came into force on 1 January 2008, and the same accounting principles and standards were applied as in the financial statements for the year ended 31 December 2019.

B.- The interim consolidated financial statements for the first half of 2020 were prepared in accordance with the International Financial Reporting Standards adopted by the European Union (EU-IFRS).

The accounting standards were applied on a uniform basis with respect to the year ended 31 December 2019.

These interim financial statements were approved by the Board of Directors of PharmaMar on 30 July 2020.

C.- Accounting estimates

The accounting estimates and judgements made by application of PharmaMar's accounting policies for 2019 are detailed in Note 2.2 to the separate financial statements of PharmaMar and Note 4 to the consolidated financial statements.

In both cases, they address the following issues:

a) Deferred tax assets
b) Recognition of revenue under licensing agreements
c) Capitalized development expenses

3. Seasonal or cyclical nature of the PharmaMar Group's transactions

Moreover, in addition to recurring sales, the Oncology segment has another type of revenues, namely, revenues from licensing and/or co-development agreements for its products. These licensing agreements involve payments on a schedule that is not uniform and normally depend on milestones that are defined in the agreement itself and

can vary considerably in terms of type and amount, and may produce sizeable variations in earnings between periods whose materialization is difficult to predict in advance.

4. Segment reporting

The disclosures by business segment are as follows:

06/30/2020	Oncology	Diagnostics	RNAi	Unallocated	Group
Revenue	163.288	5.767	0	56	169.110
Cost of sales	(2.072)	(1.783)	0	0	(3.854)
Operating expenses	(39.976)	(2.125)	(1.718)	(6.413)	(50.231)
Operating result	**121.240**	**1.860**	**(1.718)**	**(6.357)**	**115.025**
Result before income taxes	**121.682**	**1.801**	**(1.836)**	**(6.358)**	**115.290**
Total Assets	**340.317**	**8.693**	**3.197**	**20**	**352.227**
Total Liabilities	**239.149**	**3.729**	**5.840**	**11**	**248.729**
Investment fixed assets and intangible assets	**905**	**119**	**69**	**0**	**1.093**

Thousand euro

06/30/2019	Oncology	Diagnostics	RNAi	Unallocated	Group
Revenue	38.574	2.832	0	0	41.406
Cost of sales	(1.477)	(1.116)	0	0	(2.593)
Operating expenses	(41.557)	(3.755)	(1.762)	(5.418)	(52.490)
Operating result	**(4.460)**	**(2.038)**	**(1.762)**	**(5.418)**	**(13.677)**
Result before income taxes	**(6.239)**	**(2.128)**	**(1.975)**	**(5.417)**	**(15.759)**
Total Assets	**118.599**	**6.307**	**3.297**	**1.535**	**129.738**
Total Liabilities	**120.859**	**5.558**	**6.892**	**208**	**133.517**
Investment fixed assets and intangible assets	**172**	**55**	**2**	**0**	**229**

Thousand euro

For more information, see item 14 in Chapter IV of the Selected financial information and the Interim directors' report contained in Chapter VI of this document.

5. Fixed and other non-current assets: Intangible assets, Property, plant and equipment and other fixed assets

A) Separate financial statements Pharma Mar, S.A.

Intangible assets: In its separate financial statements for the first half, PharmaMar capitalized €3.5 million in development expenses related mainly to Zepzelca™ (lurbinectedin).

Moreover, regarding the licensing agreement with Jazz Pharmaceuticals referred to in section 1, PharmaMar recognized an intangible asset in connection with lurbinectedin in its separate financial statements in the amount of €117.3 million as of 31 December 2019. The fact that all economic rights to this asset in the United States had been licensed/transferred (the license granted exclusive commercialization rights for the United States) entailed derecognition of the asset for an amount equivalent to the weighting of the market that was licensed/assigned. Specifically, as of the date of entry into force of the licensing agreement, PharmaMar

derecognized €60.5 million, the amount equivalent to the weighting of the economic yields expected from the US market in proportion to the total.

The change in development expenses capitalized in the separate financial statements of PharmaMar for the first half of 2020 is as follows:

	Yondelis	Zepzelca / Lurbinectedina	Total
12/31/2019	**10.229**	**117.257**	**127.486**
Additions	0	3.479	3.479
Amortization	-9.630	0	-9.630
Derecognition	0	-60.544	-60.544
06/30/2020	**599**	**60.192**	**60.791**

Thousand euro

There were no material acquisitions of property, plant and equipment, and no disposals of fixed assets.

B) Consolidated financial statements

There were no material acquisitions of property, plant and equipment, and no disposals of fixed assets.

No impairment was recognized in connection with property, plant and equipment, intangible assets or other non-current assets in the period.

The changes in capitalized development expenses in the first half of 2020 are as follows:

	Yondelis	Zepzelca / Lurbinectedina	Total
12/31/2019	**2.130**	**3.021**	**5.151**
Additions	0	166	166
Amortization	-1.529	-29	-1.558
06/30/2020	**601**	**3.158**	**3.759**

Thousand euro

6. Inventories

No impairment was recognized as a result of writing down the carrying amount of inventories to their realizable net value, nor was any such impairment reversed.

	06/30/2020	31/12/2019
Goods for resale	897	179
Raw materials and other supplies	634	241
Semi-finished products and products in process	7.442	7.917
Finished products	603	564
Total inventories	**9.576**	**8.902**

Thousand euro

7. Customer and other accounts receivable

The detail of this account is as follows:

	06/30/2020	31/12/2019
Customer receivables for sales and services	18.075	11.471
Customer receivables loss allowance	(337)	(307)
Net	**17.737**	**11.164**
Other receivables	509	366
Supplier advances	35	0
Total Trade and other receivables	**18.282**	**11.530**

Thousand Euro

As of 30 June 2020, no customer receivables had been discounted with banks.

8. Non-current and current financial assets and Cash and cash equivalents

Non-current financial assets consist mainly of a deposit with guarantee principal whose balance amounted to €21.1 million as of 30 June 2020.

Current financial assets refer to a number of time deposits for periods of more than three months. The balance as of 30 June 2020 was €19.2 million.

Cash and cash equivalents refers mainly to deposits and other investments maturing at no more than three months from the acquisition date. The balance of that account as of 30 June 2020 was €208.9 million.

9. Shareholders' equity

As of 30 June, PharmaMar's capital stock amounted to €11,132 thousand (€11,132 as of 31 December 2019), represented by 222,649,287 shares with a par value of 5 cent each. All the shares have been fully subscribed and paid.

In March, the company decided to implement a share buyback program for at most 6,679 thousand shares (representing approximately 3% of capital stock) or at most €30 million. The program commenced on 1 April 2020 and will run until 31 March 2021. Between 1 April and 30 June 2020, 1,485,723 shares were acquired for an amount of €8,502 thousand.

On 18 June 2020, the Shareholders' Meeting resolved to perform a contra-split and cancellation of all the shares representing the Company's capital stock in exchange for newly-issued shares in the proportion of one (1) new share for every twelve (12) old shares, which raised the par value of the shares from €0.05 to €0.60. Before the contra-split, it was resolved to reduce the Company's capital stock by the amount of €0.15 by cancelling three (3) shares held by the company, each with a par value of €0.05. The new shares began trading on 22 July.

Dividends paid in the period January-June 2020

In June 2020, in accordance with the distribution of 2019 earnings approved by the Shareholders' Meeting, a dividend amounting to €0.04 gross per share, i.e. a total of €8,819 thousand, was distributed.

10. Current and non-current financial liabilities

The breakdown of non-current and current financial debt is as follows:

	6/30/2020	12/31/2019
Non current debt	**40.927**	**53.063**
Bank debt	6.109	15.291
Obligations and bonds	16.574	16.549
Govt. Agencies: R&D funding	18.244	21.223
Current debt	**18.524**	**29.655**
Credit facilities	5.197	11.583
Effects and certifications	611	2.241
Bank loan	6.845	10.497
Govt. Agencies: R&D funding	5.092	4.883
Interest and others	779	451
Total financial debt	**59.451**	**82.718**
Cash&cash equivalents + non current and current financial investment	**249.158**	**21.924**
TOTAL NET CASH / (DEBT)	**189.707**	**(60.794)**

Thousand euro

A total of €12.8 million in bank loan repayments were made through 30 June 2020. That figure includes early repayment of two banks loans whose outstanding amount was €9 million as of 1 January.

Loans from official bodies amounting to €3.3 million were repaid in the first half of 2020.

No new bank loans were arranged in the period, while €76 thousand were collected in loans from official bodies for projects that had been approved in previous years.

11. Deferred revenues

Current deferred revenues (€62.1 million) and non-current deferred revenues (€97.3 million) refer mainly to the part of the upfront and milestone payments under licensing agreements signed by the Group that, in accordance with IFRS 15, have not yet been recognized as revenues in the income statement. €61.5 million in current deferred revenues and €94.7 million in non-current deferred revenues refer to the licensing agreement with Jazz Pharmaceuticals. Deferred revenues are recognized in profit or loss over the term of the related commitments as a function of the degree of progress of the project, as the obligations set out in the contract are met.

12. Revenues

The breakdown of Group net revenues is as follows:

	06/30/2020	06/30/2019	Var.
Oncology Sales	46.950	36.291	29%
Commercial Sales	*44.334*	*35.777*	24%
API sales	*2.616*	*514*	409%
Diagnostics Sales	5.639	2.689	110%
Sales	**52.589**	**38.980**	**35%**
Royalties	**1.420**	**1.654**	**-14%**
Licences	**114.966**	**629**	
Other (Diagnostics)	**135**	**143**	
TOTAL REVENUES	**169.110**	**41.406**	**308%**

Thousand euro

Revenues in the oncology segment, amounting to €47.0 million (€36.3 million in 1H19), were almost entirely from Yondelis® sales but also include compassionate-use sales of Zepzelca™ (lurbinectedin) in some European countries, amounting to €5.9 million, and sales of Zepzelca® vials to our partners, amounting to €1.5 million. Sales of the Yondelis raw materials to partners (Janssen and Taiho) amounted to €2.6 million in the first half of 2020 (€0.5 million in the same period of 2019). Sales in this segment increased by 29% year-on-year.

Revenues in the diagnostics segment increased by 110% year-on-year to €5.6 million (vs. €2.7 million in the first half of 2019), mainly as a result of sales of the new COVID-19 diagnosis kit, which was released in March, and the distribution of the IgM/IgG antibody test for COVID-19.

Royalty revenues correspond to the Oncology segment. Royalties received from Janssen Products and Taiho Pharmaceutical Co for sales of Yondelis® in the United States, Japan and the rest of the world except the European Union amounted to €1.4 million in the first half of 2020 (€1.7 million in the same period of 2019).

Revenues from licensing and other co-development agreements, which also correspond entirely to the Oncology segment, amounted to €115 million in the first half of 2020, mostly under the licensing agreement for Zepzelca™ (lurbinectedin) in the United States with Jazz Pharmaceuticals.

The licensing agreement for Zepzelca™ (lurbinectedin) signed with Jazz Pharmaceuticals in December 2019 came into force in January and, in February, PharmaMar collected an upfront payment amounting to €181 million (USD 200 million).In June, Zepzelca™ (lurbinectedin) was approved for commercialization in the US by the FDA under the accelerated approval procedure, triggering a payment by Jazz Pharmaceuticals to PharmaMar of €88,5 million (USD 100 million). By application of the accounting standard on revenue recognition (IFRS 15), revenues from the licensing agreement are recognized on the basis of the degree of progress and/or compliance with the commitments acquired by PharmaMar under the agreement; consequently, a total of €112.4 million in revenues had been recognized as of 30 June 2020. Another €3 million were recognized as revenues under other licensing agreements.

For more information, see item 14 in Chapter IV of the Selected financial information, and the Interim directors' report contained in Chapter VI of this document.

13. Deferred tax assets and Income tax

The Group calculated its deferred tax assets as a function of the amount it estimates it will be able to recover against projected future profits; there were no changes with respect to the calculations as of 31 December 2019.

Each Group company calculates its tax expense using the tax rate applicable in each country. Effective tax rates were not used to calculate income tax presented in the consolidated income statement.

To calculate income tax, the Group availed itself of a reduction factor for revenues from the assignment of the right to use or exploit patents. Additionally, the Group offset tax losses, used international double taxation tax credits, and took deductions for research and development. As a result, the effective tax rate as of 30 June was 1.30%. The effective rate for the full year may differ from that in the first half.

14. Subsequent events

No material events have occurred since 30 June that might affect the content of the financial statements or require disclosure.

15. Risks and uncertainties in the second half of the year

As regards the segments within the biopharmaceutical area, there is the inherent risk that research and development processes may not be completed successfully, as well as the risk that a project, once completed, may not be approved by the regulatory authorities. Pressure on drug prices and discounts in Europe as a result of the adjustment measures being adopted in the countries where our product is commercialized. Risk of the entrance of generics as a result of patent expiration, and risk of loss of market exclusivity granted by regulatory agents. Additionally, the approval of new rival products may reduce net sales of our products. There is also exchange rate risk in licensing agreements whose consideration is in a currency other than the euro.

16. Related-party disclosures

See section 18 of Chapter IV Selected financial information.

INCOME STATEMENT BY FUNCTION

As provided in IAS 1.88, expenses in the income statement may be classified on the basis of their nature or function. In its consolidated financial statements, the PharmaMar Group elects to classify expenses by function. For this reason, this section contains a consolidated income statement as of 30 June 2020 by function, with the comparable figures for 30 June 2019. There is also a table reconciling expenses by nature from chapter IV with the expenses by function in the income statement used by the Group to draw up its consolidated financial statements.

The other components of the consolidated financial statements drawn up by the Group conform to the forms presented in Chapter IV of this report.

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS		
Thousand euro	**06/30/2020**	**06/30/2019**
Revenue:		
Revenue from contracts with customers	52.589	38.980
Revenue from licensing and development agreements (	114.966	629
Royalties	1.420	1.654
Other	135	143
	169.110	**41.406**
Cost of sales	(3.854)	(2.593)
Marketing expenses	(11.495)	(12.736)
General and administrative expenses	(8.439)	(6.934)
Research and development expenses	(24.252)	(27.916)
Net impairment on financial assets	(167)	(5)
Other operating expenses	(6.304)	(5.430)
Other results	426	531
Net operating result	**115.025**	**(13.677)**
Net financial results	**265**	**(2.082)**
Result of the period before income taxes	**115.290**	**(15.759)**
Income tax benefit / (expense)	(1.501)	(3.353)
Result for the period from continuing operations	**113.789**	**(19.112)**
Result for the period from discontinued operations	**0**	**(2.217)**
Equity holders of the parent company	0	(2.217)
Result for the period	**113.789**	**(21.329)**
Equity holders of the parent company	**113.808**	**(21.320)**
Non-controlling interests	(19)	(9)

Reconciliation of expenses by nature with expenses by function:

	Cost of sales	Marketing expenses	General and Administrative expenses	R&D expenses	Other operating expenses	Other results	Impairment of financial assets	Total
(+/-)Inventories variation	(2.800)	70	1.923	(515)	0	0	0	**(1.322)**
(+)In-process research and development	0	0	0	166	0	0	0	**166**
(-) Supplies	(779)	(82)	(693)	(1.310)	0	0	0	**(2.864)**
(+) Other operating income	0	0	0	0	0	58	0	**58**
(-) Personnel expenses	(196)	(5.938)	(5.779)	(9.228)	(3.911)	0	0	**(25.052)**
(-) Other operating expenses	(6)	(4.957)	(3.127)	(11.251)	(2.222)	0	(167)	**(21.730)**
(-) Amortization	(73)	(588)	(763)	(2.115)	(170)	0	0	**(3.709)**
(+)Government Grants	0	0	0	0	0	368	0	**368**
	(3.854)	**(11.495)**	**(8.439)**	**(24.252)**	**(6.304)**	**426**	**(167)**	**(54.085)**